What Clair Health Is Building and Why It Matters
Clair Health is a women’s health tracking startup developing a noninvasive wearable technology that continuously monitors key reproductive hormones, turning cyclical hormonal fluctuations into a real-time physiological signal that can inform fertility, performance, and overall well-being. The company’s seed-stage hormone tracking wearable is designed to sit at the wrist like jewelry while using a stack of biosensors to infer levels of estrogen, progesterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH). Instead of blood or urine tests, the continuous hormone monitor relies on physiological signals such as skin temperature, heart rate variability, and electrodermal activity, which are interpreted by Clair’s AI models. This approach links hormone dynamics to everyday metrics that consumers already associate with sleep, stress, and recovery, positioning Clair at the intersection of wearables, predictive health, and next-generation women’s health tech.
Funding, Founders, and the Road to Market
Clair Health funding has reached USD 11.6 million (approx. RM54.3 million) in seed capital, led by Khosla Ventures with participation from a16z speedrun and several other investors. The startup was founded by Stanford graduates Jenny Duan and Abhinav Agarwal; Duan reportedly closed the round the same week she graduated, while Agarwal brings experience from developing a noninvasive continuous glucose monitor. Clair plans to ship its hormone tracking wearable in November as a wellness product, with FDA clearance expected to follow. According to Pulse2, Clair “reports 94% accuracy in classifying menstrual cycle phases, benchmarked against daily urine samples rather than clinical blood analysis.” The company has also attracted more than 100 letters of intent from fertility clinics, signaling early interest from clinical and para-clinical partners who see promise in a continuous hormone monitor that could eventually support diagnostics.
A Jewelry-Inspired Form Factor for Continuous Hormone Monitoring
Clair’s design strategy is to make a medical-grade signal feel like a lifestyle accessory. The device is described as a jewelry-inspired hormone tracking wearable, which aims to blend into everyday outfits rather than resemble a clinical sensor. Under the polished exterior, Clair uses 10 biosensors, including biomagnetic sensors, to gather over 130 proprietary biomarkers linked to hormone fluctuations. The wearable collects signals related to skin temperature, heart rate variability, and electrodermal activity, and processes them locally with AI models. Clair says its waitlist exceeds 25,000 people and that the first 5,000 units sold out six months before release, suggesting strong consumer appetite for noninvasive wearable technology that focuses on hormones rather than only steps or sleep. By pairing consumer-friendly design with continuous hormone monitor functionality, Clair is reframing what a women’s health tracking device can look and feel like.
Redefining Female Physiology with Continuous Data
Clair argues that continuous hormone monitoring can reveal complexity in female physiology that textbook four-phase cycle models overlook. In beta testing, the company reports it has identified nine sub-phases of the menstrual cycle, more than double what many users are taught. Clair’s team frames this as evidence that “the data has always been there; we just haven’t had something to read it until now.” Their AI models even extend beyond wrist signals, analyzing voice-based biomarkers to estimate cycle phase after a short conversation. While peer-reviewed clinical data is still pending, an independent study through the Stanford Gladstone BeeHive program is underway. If future research supports these findings, women’s health tracking could move from static, calendar-based assumptions to continuous, individualized hormone maps that better capture how mood, cognition, training capacity, and recovery change across the cycle.
From Reactive Women’s Health to Predictive Wearable Platforms
Clair is entering a crowded wearables market, where, according to Rock Health’s Consumer Adoption Survey, 57% of people now own a wearable or connected device. Most devices track sleep, steps, and heart rate but treat hormones as a blind spot; Clair’s continuous hormone monitor aims to make hormones the primary signal rather than a background variable. The roadmap extends beyond fertility windows to perimenopause tracking, hormone replacement therapy calibration, and potential diagnostics for conditions such as PCOS and endometriosis. Privacy is central to the product story, with data processed on the phone and protected via zero-knowledge encryption. By shifting hormone data from occasional lab tests to real-time streams, Clair positions noninvasive wearable technology as a bridge from reactive care toward predictive, data-driven women’s health tracking that can alert users and clinicians to subtle hormonal changes before symptoms escalate.
